Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was $89.04 for the day, up 0.04% from the previous closing price of $89.0. In other words, the price has increased by $0.04 from its previous closing price. On the day, 2.54 million shares were traded. RYTM stock price reached its highest trading level at $94.8 during the session, while it also had its lowest trading level at $87.39.
Ratios:
Our analysis of RYTM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.13 and its Current Ratio is at 3.30. In the meantime, Its Debt-to-Equity ratio is 13.60 whereas as Long-Term Debt/Eq ratio is at 13.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Buy rating and assigned the stock a target price of $97.
On July 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $88.
BofA Securities Upgraded its Neutral to Buy on April 07, 2025, while the target price for the stock was maintained at $63.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 09 ’25 when CHRISTOPHER PAUL GERMAN bought 3,817 shares for $65.14 per share.
PAMELA CRAMER bought 15,572 shares of RYTM for $1,014,360 on Jul 09 ’25. On Jul 09 ’25, another insider, HUNTER SMITH, who serves as the Officer of the company, bought 42,120 shares for $65.14 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 5667404800 and an Enterprise Value of 3963481856. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.39 while its Price-to-Book (P/B) ratio in mrq is 298.39. Its current Enterprise Value per Revenue stands at 28.959 whereas that against EBITDA is -15.043.
Stock Price History:
The Beta on a monthly basis for RYTM is 2.36, which has changed by 0.78008795 over the last 52 weeks, in comparison to a change of 0.11844492 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $89.05, while it has fallen to a 52-week low of $40.61. The 50-Day Moving Average of the stock is 39.17%, while the 200-Day Moving Average is calculated to be 54.45%.
Shares Statistics:
RYTM traded an average of 706.50K shares per day over the past three months and 1337290 shares per day over the past ten days. A total of 63.49M shares are outstanding, with a floating share count of 58.19M. Insiders hold about 8.53% of the company’s shares, while institutions hold 95.50% stake in the company. Shares short for RYTM as of 1749772800 were 4757385 with a Short Ratio of 6.73, compared to 1747267200 on 5070846. Therefore, it implies a Short% of Shares Outstanding of 4757385 and a Short% of Float of 9.71.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
